We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Genetic Technologies Ltd | NASDAQ:GENE | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.04 | 1.78% | 2.29 | 2.11 | 7.77 | 2.3501 | 2.21 | 2.25 | 30,630 | 05:00:04 |
Highlights:
The paper entitled “Predicting 10-year risk of pancreatic cancer using a combined genetic and clinical model” was published in the journal Gastro Hep Advances by GTG’s scientific team including Dr Erika Spaeth, Dr Gillian Dite and Dr Chi Kuen Wong along with co-authors Dr Richard Allman and Dr Nicholas Murphy.
Pancreatic cancer has the poorest 5-year survival rate of any major solid tumour, but when diagnosed at an early stage, survival rates improve. Population screening is impractical because pancreatic cancer is rare, with a lifetime risk of 1.7%. However, accurate risk stratification in the general population will enable healthcare providers to focus early detection strategies on high-risk individuals, potentially saving lives and improving health outcomes from this devastating disease.
GTG’s Chief Commercial Officer, Carl Stubbings said, “Around 65,000 people will be diagnosed with pancreatic in the U.S. this year and 50,000 people will die3. This devastating statistic is driven by late diagnosis of this cancer. Implementing geneType risk assessment test for pancreatic cancer will help doctors diagnose the disease earlier, intervene earlier and reduce this appalling mortality. This test really can make a difference in improving patient outcomes.”GTG’s CEO, Simon Morriss added, “We are proud to be able to offer this doctor prescribed risk assessment test, as we believe it can lead to significant improvement to the survival rate of such a dreadful disease.”
Compared to a traditional clinical risk score, geneType for pancreatic cancer showed nearly a 50% improvement in identifying patients at a high risk of developing pancreatic cancer—these adults had 4-times the population risk.
Enquiries
Investor RelationsAdrian MulcahyAutomic MarketsM: +61 438 630 411E: adrian.mulcahy@automicgroup.com.au
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
__________________
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396775/2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396775/3 https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html
1 Year Genetic Technologies Chart |
1 Month Genetic Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions